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Objective Effects of conventional and atypical antipsychotics on bone mineral density (BMD) and serum prolactin levels (PRL) were
examined in patients with schizophrenia.
Methods One hundred and sixty-three ﬁrst-episode inpatients with schizophrenia were recruited, to whom one of three conventional
antipsychotics (perphenazine, sulpiride, and chlorpromazine) or one of three atypical antipsychotics (clozapine, quetiapine, and aripiprazole)
was prescribed for 12months as appropriate. BMD and PRL were tested before and after treatment. Same measures were conducted in 90
matched healthy controls.
Results Baseline BMD of postero-anterior L1–L4 range from 1.04 ± 0.17 to 1.42 ± 1.23, and there was no signiﬁcant difference between
the patients group and healthy control group. However, post-treatment BMD values in patients (ranging from 1.02 ± 0.15 to 1.23 ± 0.10) were
signiﬁcantly lower than that in healthy controls (ranging from 1.15 ± 0.12 to 1.42 ± 1.36). The BMD values after conventional antipsychotics
were signiﬁcantly lower than that after atypical antipsychotics. The PRL level after conventional antipsychotics (53.05 ± 30.25 ng/ml) was
signiﬁcantly higher than that after atypical antipsychotics (32.81 ± 17.42 ng/ml). Conditioned relevance analysis revealed signiﬁcant negative
correlations between the PRL level and the BMD values after conventional antipsychotics.
Conclusion The increase of PRL might be an important risk factor leading to a high prevalence of osteoporosis in patients with schizophrenia
on long-term conventional antipsychotic medication. Copyright © 2014 John Wiley & Sons, Ltd.
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INTRODUCTION
Schizophrenia is a chronic, severe, and disabling mental
disorder. The prevalence of schizophrenia approaches
1%, and the incidence is about 1.5 per 10,000 people
(McGrath et al., 2008; Van Os and Kapur, 2009).
Although the incidence is low, the prevalence is high
due to chronicity. It currently affects 24 million people
(World Health Organization, 2011) and is considered to
be one of the top ten causes of long-term disability
worldwide. In most cases, schizophrenia starts between
the ages of 15 and 35years, and approximately 75% of
patients have ongoing disability with relapses; therefore,
long-term use of antipsychotics is needed to achieve
stable condition and reduce recurrence.
Osteoporosis is a systemic skeletal metabolic
disorder characterized by a reduction in bone mineral
density (BMD), which leads to an increased risk of
fracture (World Health Organization, 1994; Alldredge
et al., 2009). Research has shown that patients with
schizophrenia have a higher incidence rate of developing
osteoporosis; the mechanism underlying this is multifacto-
rial and includes general as well as disease-speciﬁc factors,
such as antipsychotic medication and hyperprolactinemia
(Javaid and Holt, 2008). Therefore, the increasing aware-
ness of the effect of antipsychotics on bone metabolism
may prompt clinicians to screen patients at high risk of
antipsychotic-induced osteoporosis and reduce the
incidence of potentially avoidable fractures (Howard
et al., 2007; Renn et al., 2009; Partti et al., 2010; Graham
et al., 2011). Research has also indicated that some risk
factors may contribute to the development of osteoporo-
sis in patients with schizophrenia, such as inadequate
intake of nutrition, excessive thirst, low activity, excessive
smoking, and alcohol abuse. In addition, the occurrence of
osteoporosis has been linked to themetabolism of antipsy-
chotics. Such drugs usually need to be metabolized in the
liver and kidney, and long-term usage can damage liver
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function, leading to a synthetic reduction of vitamin D,
which promotes calcium absorption by the gastrointestinal
system. In addition, the sedative effects of some antipsy-
chotics reduce patients’ outdoor activity, which further
limits calcium absorption.
Antipsychotics are the most common cause of phar-
macologic hyperprolactinemia (Molitch, 2005). Some
conventional antipsychotics have been found to
regulate prolactin secretion, whereas most atypical an-
tipsychotics do not (Kaneda et al., 2004; Montejo,
2008). A study of 422 psychotic patients showed that
antipsychotic therapy is strongly associated with
hyperprolactinemia; in particular, a signiﬁcantly
higher prevalence of hyperprolactinemia was found
in the conventional antipsychotics-treated patients
compared with the atypical antipsychotics-treated
patients group (Montgomery et al., 2004). Some
recent research suggests that antipsychotic-related
hyperprolactinemia may lead to osteoporosis and
fragility fractures (Rey-Sánchez et al., 2009; Roke
et al., 2009), whereas other studies reported contradic-
tory ﬁndings (Lee et al., 2010; Renn et al., 2010;
Sugawara et al., 2011). Therefore, the relationship
between hyperprolactinemia and osteoporosis remains
controversial, and further research is warranted.
This study aimed to investigate how long-term use of
conventional and atypical antipsychotics affects spine
BMD cross postero-anterior (PA) L1–L4 and how it is
associated with PRL in patients with schizophrenia. This
is the ﬁrst study to compare the effects of two generations
of antipsychotics on both BMD and PRL in a 12-month
follow-up and provides important evidence for interven-
tion strategies for osteoporosis in schizophrenia.
METHODS
Participants
All participants (aged between 25 and 45 years) who
met the diagnostic criteria for schizophrenia based on
the International Classiﬁcation of Diseases 10th revi-
sion were recruited from Shandong Mental Health
Center, China. They were all inpatients with ﬁrst-epi-
sode schizophrenia during the period of recruitment
(from May 2010 to April 2012), with a total score of
≥60 on the Positive and Negative Symptoms Scale
(PANSS). All patients had an educational level of
primary school or above, which enabled them to
understand study information and give informed
consent. Individuals with serious neurological and
physical diseases that may cause osteoporosis or bone
metabolism and those with a history of alcohol or drug
abuse were excluded.
Two hundred and forty eligible patients completed a
questionnaire booklet regarding their sociodemographic
status and clinical features. BMDmeasure of PAL1–L4,
serum prolactin level (PRL), estrogen (E2), bone alka-
line phosphatase (BALP), and crosslaps (CTX) were
examined on the day of admission and again 12months
after antipsychotic treatment. All patients were
randomly allocated to single dosage of the conventional
antipsychotics group (n= 120) with 40 cases in each of
the chlorpromazine, perphenazine, and sulpiride sub-
groups, and atypical antipsychotics group (n= 120) with
40 cases in each of the clozapine, quetiapine, and
aripiprazole subgroups.
Ninety healthy controls were also recruited during
the same period from the community in Jinan City,
Shandong Province. Their age, gender, body mass
index (BMI), marital status, and years of education
matched those of the patients group.
The study protocol was approved by the Research
Ethics Committee of Shandong University, and prior
written informed consent was obtained from all
participants.
Medications-antipsychotics options
Conventional antipsychotics: chlorpromazine 25mg per
tablet manufactured by Beijing YiMin Pharmaceuticals,
perphenazine 2mg per tablet manufactured by Tianjin
Lisheng Company, and sulpiride 100mg per tablet
manufactured by Jiangsu Xuzhou Pharmaceuticals.
Atypical antipsychotic: clozapine 25mg per tablet
manufactured by Jiangsu Yunyang Pharmaceuticals,
quetiapine 200mg per tablet manufactured by
Astrazeneca, and aripiprazole 5mg per tablet
manufactured by Zhejiang Otsuka pharmaceuticals.
The use and dosage of antipsychotics were
prescribed by consultant psychiatrists according to
patients’ conditions. The range and average dosage
prescribed were chlorpromazine 300 ~ 600mg/
day (325.0 ± 47.63mg/day), perphenazine16 ~ 48mg/
day (30.0 ± 7.82mg/day), sulpiride 600 ~ 1200mg/day
(800.0 ± 144.01mg/day); clozapine 200~ 400mg/day
(318.75 ± 21.10mg/day), quetiapine 400 ~ 750mg/
day (650.0±62.36mg/day), and aripiprazole 10~30mg/
day (18.25±7.86mg/day). No other medications were
prescribed except for a small dosage of benzodiazepine
drugs (2 ~4mg/night) and benzhexol (2 ~8mg/day).
Measures
Questionnaires. Psychotic symptoms were assessed
by PANSS (Kay et al., 1988), which is a medical scale
used for measuring symptom severity of patients with
schizophrenia. It is widely used in the study of antipsy-
chotic therapy. A general questionnaire was designed
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and used to collect demographic information such as age,
gender, weight, educational level, economic situation, and
marital status; and clinical data such as medical history,
duration of disease, diagnostic classiﬁcation, and current
medications, which were obtained from medical records.
Measure of bone mineral density. The most widely
validated technique, the dual-energy X-ray absorptiome-
try (by American General Medical Equipment Co.),
was used to measure BMD. The BMD measure of PA
L1–L4 (g/cm2) was detected by the application of
dual-energy two-photon reuptake X-ray measurement,
and the scanned image was based on the surface bone
density of 1.001 g/cm2. Quality assurance was carried
out before assessment with a deviation of 0.46% and
coefﬁcients of variation of 0.08%. According to the
World Health Organization (WHO) criteria, osteopo-
rosis is deﬁned as a BMD that lies 2.5 SD or more
below the average value for young healthy women
(a t-score of< 2.5 SD) (World Health Organization,
2004; Kanis et al., 2008). This criterion has now been
widely accepted and provides both a diagnostic and
intervention threshold. Therefore, the WHO criterion
was adopted in this study.
Measure of prolactin levels. A total of 8ml of fasting
blood sample was collected at 7:00 AM on the next day
of admission from each participant and again
12months later. Three milliliters of blood sample
was used to measure serum PRL level and E2 by
electrochemical luminescence method. The sample
count coefﬁcient of variation was ≤3.49%, according
to the WHO standards. In this study, we used the 601
Electrochemical Luminescence Counting Instrument
manufactured by the Diagnostics Division of German
Company Roche. Five milliliters of blood was used
to detect serum levels of BALP and C-terminal
telopeptides of type I collagen.
Study design and procedure. This is a prospective
study design. All participants were invited to the
clinical laboratory in Shandong Mental Health Center
at both baseline and 12months later. After blood
samples were taken, their BMD was measured by X-ray
absorptiometry. They were then instructed to complete a
questionnaire booklet before they left the laboratory.
The same measures were conducted 12months later.
Statistics analysis. Data analysis was conducted using
SAS version 9.1 (SAS Institute Inc, Cary, NC, USA).
Demographic and clinical features were compared
between groups using independent samples t-tests, conti-
nuity corrected Chi-square tests (Yates’ correction) as
appropriate. Comparisons of BMD value, PRL level,
E2, BALP, and CTX among conventional, atypical,
and control groups were conducted using paired t-test
before and after treatment. The association between the
PRL level and the BMD value after treatment in both
conventional and atypical groups was examined using
Pearson’s correlation analysis. Multivariate logistic
regression (backward stepwise) modeling was conducted
to explore the effect of baseline variables on BMD
measure (z-core) at 12months.
RESULTS
Demographic and clinical characteristics
During the study, 28 patients had to switch to other
antipsychotics because of poor therapeutic beneﬁts or
side effects, 33 patients dropped out because of
withdrawal and loss of contact, and 16 patients needed
to combine treatment with another medication. In total,
77 patients dropped out of the study, and therefore the
drop-out rate was about 32.08%. Of those, 39 cases
dropped out from the conventional group (chlorprom-
azine 14 cases, perphenazine 13 cases, and sulpiride
12 cases), with a drop-out rate of 32.50%; and 38 cases
dropped out from the atypical group (clozapine 14
cases, quetiapine 12 cases, and aripiprazole 12 cases),
with a drop-out rate of 31.66%. The drop-out rates
were roughly equivalent for conventional and atypical
antipsychotics, and consistent with that reported in a
meta-analysis, which indicates that drop-out rates
exceed a third of patients treated with antipsychotic
medication in clinical trials (Wahlbeck et al., 2001;
Lieberman et al., 2005). A total of 163 patients
completed the study, including 81 cases in the conven-
tional group and 82 cases in the atypical group. Demo-
graphic and clinical characteristics are presented in
Table 1. There were no signiﬁcant differences
between the patient group (including both the conven-
tional group and the atypical group) and the healthy
control group in terms of age, BMI and education,
gender, and marital status (p> 0.05 in all cases). In ad-
dition, there were no signiﬁcant differences between
patients in the conventional group and the atypical
group in terms of age, BMI, total score of the PANSS,
education, disease duration, gender, and subtypes of
schizophrenia (p> 0.05 in all cases, see Table 1).
Comparison of bone mineral density measure
between groups
There were no signiﬁcant differences of BMD values of
PA L1–L4 between the control group and the two patient
groups (conventional and atypical group) before
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treatment (p> 0.05). However, the BMD value of the
conventional group was signiﬁcantly lower than that of
the control group at 12months after treatment, whereas
there was no difference between the atypical group and
the control group (p> 0.05) (see details in Table 2).
In comparison with pre-treatment, the BMD value in
the conventional group decreased signiﬁcantly after
treatment; the BMD value in the atypical group
decreased slightly at 12months after treatment but
failed to reach any signiﬁcance (p> 0.05). When
comparing the BMD value of the conventional group
to the atypical group, there was no signiﬁcant difference
before treatment (p> 0.05), whereas the BMD value of
the conventional group was signiﬁcantly lower than that
of the atypical group at 12months after treatment.
The study also compared incidence rates of osteopo-
rosis in the patient group and the control group at
pre-treatment baseline and 12months after treatment
and at L1–L4, respectively. The ﬁnding indicates that
the patient group had a signiﬁcantly higher osteoporo-
sis incidence rate than the control group at 12
months after treatment across PA L1–L4 level
(χ2=18.793 ~ 31.199, p< 0.05 in all cases).
Comparison of prolactin levels, estrogen, bone alkaline
phosphatase, and crosslaps between groups
The study also compared the values of PRL, E2,
BALP, and CTX between conventional and atypical
groups, before and after treatment. In the conventional
group, the PRL after treatment was signiﬁcantly
higher, and both E2 and BALP were signiﬁcantly
lower than that before treatment; however, there were
no signiﬁcant treatment effects on PRL, E2, BALP,
and CTX in the atypical group, details as shown in
Table 3.
Table 1. Comparison of demographic and clinical characteristics
Conventional (n= 81) Atypical (n= 82) Control (n= 90)
Age (years, mean ± SD) 35.9 ± 11.1 33.1 ± 10.3 34.2 ± 10.6
Sex (male) 43 (53%) 43 (52%) 47 (52%)
BMI (mean ± SD) 25.7 ± 2.2 26.8 ± 1.9 25.3 ± 2.7
Age of onset (years, mean ±SD) 27.0 ± 8.9 26.2 ± 9.7
Duration of illness (years, mean ± SD) 0.7 ± 0.4 0.6 ± 0.5
Education (years, mean ±SD) 12.9 ± 3.11 12.1 ± 2.3
Subtype of schizophrenia
Undifferentiated 33% 36%
Paranoid 59% 58%
Other schizophrenia 7% 7%
PANSS total score (mean± SD)
Before treatment 86.7 ± 17.5 87.4 ± 18
After treatment 50.4 ± 13 44.4 ± 13.7
n, number of participants. Student’s t-tests were performed between the following: the conventional group versus the atypical group, the conventional group
versus the control group, and the atypical group versus the control group (p> 0.05 in all cases).
PANSS, Positive and Negative Symptoms Scale.
Table 2. Comparison of bone mineral density measure (g/cm2) between patients and controls
Lumbar Conventional (n= 81) Atypical (n= 82) Controls (n= 90) t1 (p1) t2 (p2) t3 (p3) t4 (p4)
L1 before 1.08 ± 0.16 1.04 ± 0.17 1.16 ± 0.12 3.714 5.437 3.938* 0.549
after 1.05 ± 0.07 1.02 ± 0.15 1.15 ± 0.12 (0.09) (0.12) (0.009) (0.512)
L2 before 1.19 ± 0.18 1.12 ± 0.17 1.24 ± 0.12 3.172 5.389 3.419* 0.553
after 1.13 ± 0.11 1.10 ± 0.19 1.25 ± 0.12 (0.06) (0.14) (0.014) (0.647)
L3 before 1.25 ± 0.17 1.14 ± 0.17 1.42 ± 1.23 1.672 0.714 1.476* 1.947
after 1.20 ± 0.12 1.15 ± 0.16 1.42 ± 1.36 (0.17) (0.35) (0.048) (0.502)
L4 before 1.26 ± 0.19 1.14 ± 0.15 1.28 ± 0.15 0.916 1.982 2.452* 0.832
after 1.23 ± 0.10 1.16 ± 0.18 1.28 ± 0.13 (0.39) (0.08) (0.03) (0.767)
t1 (p1), the conventional group before treatment versus the control group at baseline.
t2 (p2), the atypical group before treatment versus the control group at baseline.
t3 (p3), the conventional group versus the control group 12months after treatment.
t4 (p4), the atypical group versus the control group 12months after treatment.
L1, lumbar vertebra1; L2, lumbar vertebra 2; L3, lumbar vertebra 3; L4, lumbar vertebra 4.
*p< 0.05.
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Correlation between prolactin levels, estrogen, bone
alkaline phosphatase, crosslaps, and bone mineral
density in treatment groups
Results from the correlation analysis among BMD and
PRL, E2, BALP, CTX in both conventional and atyp-
ical groups are shown in Table 4. In the conventional
group, the BMD value was negatively correlated with
PRL and CTX across L1–L4 at 12months after
treatment, whereas a positive correlation was found
between E2, BALP, and BMD (p< 0.05). However,
there was no signiﬁcant correlation between PRL,
E2, BALP, CTX, and BMD in the atypical group
(p> 0.05).
Multivariate logistic regression analysis
Age, gender, BMI, duration of illness, education,
PANSS score, antipsychotic treatments (conventional
or atypical), PRL, E2, BALP, and CTX were entered
as covariates into a multivariate logistic regression
model using backward stepwise method, with BMD
z-score (derived from the ratio of patients BMD mea-
sure to age-matched healthy controls’ BMD measure)
at 12months as the dependent variable (Table 5). The
use of conventional antipsychotics, PRL, and CTX
was entered into the regression equation and remained
signiﬁcant in the resultant model.
DISCUSSION
This study investigated how long-term use of antipsy-
chotics affects BMD and how this is associated with
PRL in patients with schizophrenia. The study compared
effects of two generations of antipsychotics (both conven-
tional and atypical) on BMD and its association with PRL
at baseline and 12months after treatment. The study found
that the BMD value of patients taking conventional anti-
psychotics (chlorpromazine, perphenazine, and sulpiride)
Table 3. Comparison of prolactin levels, estrogen, bone alkaline
phosphatase, and crosslaps between treatment groups
Conventional (n= 81) Atypical (n= 82)
PRL Before 31.73± 22.18 29.79 ± 16.03
(ng/ml) After 53.05± 30.25a* 32.81 ± 17.42b *
E2 Before 45.23± 10.77 47.02 ± 14.31
(U/l) After 22.87± 12.14a* 45.99 ± 17.19b *
BALP Before 26.32± 5.48 27.78 ± 4.97
(ng/ml) After 20.17± 5.34a* 28.10 ± 5.19b *
CTX Before 0.45 ± 0.23 0.50 ± 0.19
(U/l) After 0.50 ± 0.12 0.55 ± 0.12
PRL, prolactin level; E2, estrogen; BALP, bone alkaline phosphatase; CTX,
crosslaps.
aThe conventional group before treatment versus after treatment.
bThe conventional group versus the atypical group after treatment.
*p< 0.05.
Table 4. Correlations between bone mineral density and prolactin levels, estrogen, bone alkaline phosphatase, crosslaps from the conventional and atypical
groups before and after treatment
Conventional group (n= 81) Atypical group (n= 82)
PRL E2 BALP CTX PRL E2 BALP CTX
L1 Before 0.051 0.312 0.035 0.023 0.046 0.170 0.046 0.401
After 0.981* 0.784* 0.323* 0.731* 0.410 0.305 0.493 0.472
L2 Before 0.061 0.024 0.013 0.037 0.074 0.075 0.031 0.316
After 0.812* 0.543* 0.069* 0.931* 0.419 0.269 0.532 0.219
L3 Before 0.028 0.435 0.023 0.328 0.026 0.112 0.301 0.421
After 0.984 0.568* 0.069* 0.054* 0.426 0.302 0.721 0.439
L4 Before 0.043 0.482 0.003 0.062 0.009 0.129 0.032 0.236
After 0.567* 0.505* 0.997* 0.837* 0.315 0.409 0.480 0.473
PRL, prolactin level; E2, estrogen; BALP, bone alkaline phosphatase; CTX, crosslaps.
*p< 0.05.
Table 5. Logistic regression analysis of predictors for post-treatment bone mineral density z-score
Model B SE Beta t P
Constant 3.410 4.571 0.703 0.455
Conventional antipsychotics 0.621 0.149 0.422 3.917 0.000**
PRL 1.642 0.541 0.339 3.036 0.004*
CTX 0.001 0.021 0.257 2.150 0.029*
PRL, prolactin level; CTX, crosslaps.
*p< 0.05.
**p< 0.001.
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decreased signiﬁcantly 12months after treatment, and that
this is signiﬁcantly correlated with PRL level, whereas no
signiﬁcant change was found in patients taking atypical
antipsychotics (quetiapine, risperdal, and clozapine). The
study also indicates that the incidence rate of osteoporosis
(11.4 ~21.7%) across L1–L4 increased signiﬁcantly
12months after conventional antipsychotic treatment in
patients with schizophrenia, and this was signiﬁcantly
higher than that of healthy controls (0 ~ 1.6%).
One of the currently accepted hypotheses for the
pathogenesis of schizophrenia is the hyperactivity of
dopamine and serotonin (5-HT) function. PRL secre-
tion is regulated by both the prolactin release factor
and the prolactin inhibitory factor (PIF). Serotonin
(5-HT) receptors can promote prolactin release factor
secretion, whereas dopamine receptors promote PIF
secretion. Normal level of PRL is under this dual
control. Antipsychotic drugs tend to block dopamine
D2 receptors, which attenuates the inhibitory effect of do-
pamine on prolactin release, leading to hyperlactinemia.
Typical antipsychotics are not particularly selective and
also block dopamine receptors in the mesocortical,
tubero-infundibular, and the nigrostriatal pathways.
Atypical antipsychotic drugs have a similar blocking
effect on D2 receptors, and some also block or partially
block serotonin receptors (particularly 5-HT2A, C and
5-HT1A receptors). However, atypical antipsychotics
appear not to block dopamine within the tubero-infundib-
ular tract, a dopamine pathway that also controls prolactin
secretion (Emiliano and Fudge, 2004; Hummer and
Huber, 2004). The current study indicated a signiﬁcantly
higher level of PRL after long-term use of conventional
antipsychotics but not atypical antipsychotics. The lack
of prolactin elevation reported with the atypical antipsy-
chotics may be due to their much greater speciﬁcity,
which results in fewer blockades of dopamine receptors
in the tubero-infundibular pathway and some of their
effects on 5-HT2 receptors (Petty, 1999; Halbreich and
Kahn, 2003; Kishimoto et al., 2005; Peveler et al.,
2008; Walters and Jones, 2008; Riecher-Rössler et al.,
2009). In addition, perhaps a dynamic balance between
bone formation and bone resorption is essential. Basic
and clinical studies have shown that E2 can prevent bone
loss and reduce the incidence of bone fractures, and the
underlying basis of this protective effect involves the
prevention of apoptosis in osteoblasts and the inhibition
of caspase-3 activity (Ataya et al., 1988; Bradford
et al., 2010).
Kameda et al. (1997) found that E2 inhibited
hydrogen ion release, which may directly suppress
the absorption functions of osteoclasts. Goodman
et al. (2007) also reported that the incidence of
osteoporosis may be related to E2 level. It has been
proposed that the beneﬁcial effects of E2 are due to the
ability of E2 to suppress osteoclastogenic cytokine pro-
duction in T-cells and osteoblasts and to induce the apo-
ptotic death of osteoclasts (Krum and Brown, 2008).
However, because of lack of large sample size and lack
of longitudinal design, the association between E2 and
osteoporosis is not yet fully unraveled.
Bone alkaline phosphatase is a biochemical index of
bone formation, whereas CTX is a biochemical index of
bone absorption. In this study, serum BALP level in the
conventional antipsychotic group reduced signiﬁcantly
after treatment, whereas CTX level increased signiﬁcantly
after treatment. There were no changes of either BALP or
CTX level in the atypical antipsychotic group.
Findings from this study suggest that long-term use
of conventional antipsychotics produces treatment
effects by blocking dopamine D2 receptors; however,
they also interfere with the endocrine system and
metabolism. The inhibition of the hypothalamus on
the pituitary gland may decrease PIF and E2 secretion
and increase PRL secretion. This then affects the activ-
ity of bone cells, causing increased osteoclast activity,
reduced bone formation, increased bone absorption,
and unbalanced reconstruction, resulting in reduced
bone mineral density and causing osteoporosis.
Although the idea that antipsychotics may lead to
osteoporosis through the development of hyperp-
rolactinemia has been studied before, the strength of
current study is that it investigates patients with
ﬁrst-episode psychosis using a 12-month prospective
cohort design. The further strength is the random
allocation of treatments. Given that very few studies that
longitudinally examined the impact of antipsychotic-
induced hyperprolactinemia on bone metabolism, this
study is the largest comparedwith earlier evidence; there-
fore, the ﬁndings from this study are very important. One
limitation of the study is the lack of clinical assessment of
more risk factors for osteoporosis rather than age, gender,
and BMI, which should be assessed in future research.
The ﬁndings of the current study are consistent with
those of Meaney et al. (2004) who found that patients
with schizophrenia on long-term antipsychotic medica-
tion are at high risk of developing reduced bone mineral
density and suggested that this may be a consequence of
hyperprolactinemia-induced hypogonadism. The study
provides further research evidence on this and suggests
that the increase of PRL level is an important risk factor
leading to osteoporosis after long-term use of some
conventional antipsychotics. In comparison, most
atypical antipsychotics do not affect PRL level. Therefore,
when prescribing antipsychotics for long-term use in
chronic schizophrenia, the awareness of an elevated risk
of drug-induced osteoporosis is beneﬁcial for both
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clinicians and patients. However, decreased BMD and
osteoporosis are multifactorial processes, and abnor-
mal bone structure and functions are not limited to
BMD (Halbreich, 2007). Multiple dynamic processes
may lead to the impairment of bone homeostasis.
Future research using comprehensive and multifacto-
rial approaches is warranted to develop relevant
treatment and prevention strategies.
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